Choosing the Right Genomic Test in Oncology: Understanding 8 Types of Essential Genomic Tests in Oncology

In cancer care, the most important decisions are made at the very beginning. Choosing the wrong genomic test — or interpreting incomplete molecular information — can lead to delayed treatment, ineffective therapy, unnecessary toxicity, or missed therapeutic opportunities. Precision oncology is not simply about advanced technology; it is about selecting the right test at the right time for the right patient.

Modern cancer diagnosis now goes beyond histopathology alone. While morphology remains essential, understanding the genetic drivers of a tumor has become central to determining prognosis, therapeutic strategy, and long-term management. Below are eight key categories of genomic testing in oncology that shape today’s precision medicine landscape.

1. Somatic (Tumor) Testing and Tumor Profiling

Somatic testing, also known as tumor profiling, analyzes DNA extracted directly from tumor tissue to identify acquired mutations that drive cancer growth. These mutations are not inherited; they develop within the cancer cells themselves. Identifying these alterations enables clinicians to match patients with targeted therapies designed to inhibit specific molecular pathways.

For example, detection of an EGFR mutation in lung cancer may guide the use of EGFR inhibitors. Tumor profiling has become a standard component of treatment planning in many solid tumors, ensuring that therapy is biologically aligned with the tumor’s molecular characteristics.

2. Germline Testing for Inherited Cancer Risk

Germline testing evaluates inherited genetic variants present in every cell of the body. Unlike somatic mutations, these changes are passed down through families and may significantly increase lifetime cancer risk.

Testing for mutations in genes such as BRCA1 and BRCA2 can identify individuals at higher risk of developing breast, ovarian, prostate, and other cancers. Beyond guiding treatment, germline testing supports preventive strategies, enhanced surveillance, and family risk assessment. It shifts oncology from reactive treatment to proactive risk management.

3. Liquid Biopsy

Liquid biopsy represents one of the most transformative developments in oncology diagnostics. Instead of analyzing tumor tissue, this minimally invasive approach detects cancer-related biomarkers in blood samples.

It commonly measures circulating tumor DNA (ctDNA) or circulating tumor cells (CTCs) that are shed from tumors into the bloodstream. Liquid biopsy is particularly valuable when tissue biopsy is not feasible, when tumors are difficult to access, or when repeated sampling is required. It is widely used for monitoring treatment response, detecting minimal residual disease, and identifying emerging resistance mutations over time.

4. Prognostic and Predictive Gene Expression Testing

Gene expression assays evaluate how actively certain genes are being expressed within tumor cells. These tests provide insights beyond the presence or absence of mutations.

Prognostic tests estimate the risk of recurrence or progression, helping clinicians determine whether a cancer is likely to behave aggressively. Predictive tests estimate the likelihood that a patient will benefit from specific therapies, such as chemotherapy or hormonal treatment. By refining treatment decisions, these tests help avoid overtreatment and reduce unnecessary side effects, improving both clinical outcomes and quality of life.

5. Whole Exome Sequencing (WES) and Whole Genome Sequencing (WGS)

Whole exome sequencing and whole genome sequencing offer comprehensive genomic analysis. WES focuses on the protein-coding regions of genes, while WGS analyzes the entire genome.

These high-throughput approaches are particularly valuable in advanced, treatment-resistant, or rare cancers where standard panels may not reveal actionable findings. They can uncover rare, novel, or complex genomic alterations that may open the door to clinical trials or experimental therapies. Comprehensive sequencing expands diagnostic possibilities when conventional testing reaches its limits.

6. Single-Gene Testing

Single-gene testing remains highly relevant in specific clinical contexts. When a particular gene alteration is strongly associated with a disease, targeted testing may be sufficient and efficient.

For example, testing for the BCR-ABL1 fusion gene is critical in suspected chronic myeloid leukemia. In such cases, a focused approach provides rapid and clinically decisive information.

7. Multi-Gene Panels

Multi-gene panels evaluate several clinically relevant genes simultaneously. They are widely used in cancers such as breast, lung, and colorectal cancer.

Compared to sequential single-gene testing, panels are more efficient, cost-effective, and comprehensive. They allow clinicians to detect multiple actionable mutations in a single assay, streamlining diagnosis and expediting treatment decisions. Multi-gene panels have become a cornerstone of routine oncology practice.

8. Pharmacogenomic Testing

Pharmacogenomics assesses how an individual’s genetic makeup influences drug metabolism and response. In oncology, this is particularly important in minimizing treatment-related toxicity.

For instance, variations in the DPYD gene can increase the risk of severe toxicity from fluoropyrimidine chemotherapy. Identifying such variants before treatment allows clinicians to adjust dosage or select alternative therapies, enhancing patient safety and optimizing therapeutic effectiveness.

The Impact of Applying Genomic Testing Correctly

When genomic testing is selected and applied appropriately, the benefits are substantial. Patients receive more effective and personalized treatments. The risk of avoidable side effects decreases. Clinical outcomes improve. Quality of life is preserved.

Precision oncology is not about ordering more tests; it is about strategic, informed testing aligned with each patient’s unique clinical scenario.

---

Comprehensive Oncology Genomic Testing at AGTC Genomics

At AGTC Genomics, we provide comprehensive coverage across all eight categories of oncology genomic testing — from inherited cancer risk assessment and tumor profiling to advanced sequencing, liquid biopsy, gene expression analysis, and pharmacogenomic evaluation.

Our advanced genomics laboratory supports clinicians and patients across the entire cancer care continuum, enabling evidence-based treatment selection, therapy monitoring, and long-term management for various cancer types.

In precision oncology, clarity drives confidence. The right genomic test is not just a diagnostic tool — it is the foundation upon which effective cancer treatment is built.